Proteomic strategies in bladder cancer: From tissue to fluid and back

Pavel Gromov; José M.A. Moreira; Irina Gromova; Julio E. Celis

doi:10.1002/prca.200780163

Proteomic strategies in bladder cancer: From tissue to fluid and back

Pavel Gromov^*, José M.A. Moreira, Irina Gromova, Julio E. Celis

^*Corresponding author for this work

9 Citations (Scopus)

Abstract

We have applied protein expression profiling technologies in combination with immunohistochemistry, using fresh tissue and urine samples, to assess bladder cancer heterogeneity and prognosis as well as to generate protein markers for tumor progression and early diagnosis of the disease. Here, we review some selected lines of investigation and approaches undertaken by our laboratory, drawing on more than 15 years of experience in bladder cancer pboteomics, to high-light a number of issues that may be useful for researchers entering the field. In particular, we address the identification of markers for bladder cancer progression and exemplify the potential of gel-based proteomic profiling of urine samples for the early detection of urothelial carcinomas. In addition, we provide a brief description of a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the tumor microenvironment.

Original language	English
Journal	Proteomics - Clinical Applications
Volume	2
Issue number	7-8
Pages (from-to)	974-988
Number of pages	15
ISSN	1862-8346
DOIs	https://doi.org/10.1002/prca.200780163
Publication status	Published - 1 Jul 2008

Keywords

Bladder cancer biomarkers
Non-invasive diagnosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/prca.200780163

Cite this

@article{031932d8937245b49f28b6c4ec7e35de,

title = "Proteomic strategies in bladder cancer: From tissue to fluid and back",

abstract = "We have applied protein expression profiling technologies in combination with immunohistochemistry, using fresh tissue and urine samples, to assess bladder cancer heterogeneity and prognosis as well as to generate protein markers for tumor progression and early diagnosis of the disease. Here, we review some selected lines of investigation and approaches undertaken by our laboratory, drawing on more than 15 years of experience in bladder cancer pboteomics, to high-light a number of issues that may be useful for researchers entering the field. In particular, we address the identification of markers for bladder cancer progression and exemplify the potential of gel-based proteomic profiling of urine samples for the early detection of urothelial carcinomas. In addition, we provide a brief description of a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the tumor microenvironment.",

keywords = "Bladder cancer biomarkers, Non-invasive diagnosis",

author = "Pavel Gromov and Moreira, {Jos{\'e} M.A.} and Irina Gromova and Celis, {Julio E.}",

year = "2008",

month = jul,

day = "1",

doi = "10.1002/prca.200780163",

language = "English",

volume = "2",

pages = "974--988",

journal = "Proteomics - Clinical Applications",

issn = "1862-8346",

publisher = "Wiley - V C H Verlag GmbH & Co. KGaA",

number = "7-8",

}

TY - JOUR

T1 - Proteomic strategies in bladder cancer

T2 - From tissue to fluid and back

AU - Gromov, Pavel

AU - Moreira, José M.A.

AU - Gromova, Irina

AU - Celis, Julio E.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - We have applied protein expression profiling technologies in combination with immunohistochemistry, using fresh tissue and urine samples, to assess bladder cancer heterogeneity and prognosis as well as to generate protein markers for tumor progression and early diagnosis of the disease. Here, we review some selected lines of investigation and approaches undertaken by our laboratory, drawing on more than 15 years of experience in bladder cancer pboteomics, to high-light a number of issues that may be useful for researchers entering the field. In particular, we address the identification of markers for bladder cancer progression and exemplify the potential of gel-based proteomic profiling of urine samples for the early detection of urothelial carcinomas. In addition, we provide a brief description of a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the tumor microenvironment.

AB - We have applied protein expression profiling technologies in combination with immunohistochemistry, using fresh tissue and urine samples, to assess bladder cancer heterogeneity and prognosis as well as to generate protein markers for tumor progression and early diagnosis of the disease. Here, we review some selected lines of investigation and approaches undertaken by our laboratory, drawing on more than 15 years of experience in bladder cancer pboteomics, to high-light a number of issues that may be useful for researchers entering the field. In particular, we address the identification of markers for bladder cancer progression and exemplify the potential of gel-based proteomic profiling of urine samples for the early detection of urothelial carcinomas. In addition, we provide a brief description of a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the tumor microenvironment.

KW - Bladder cancer biomarkers

KW - Non-invasive diagnosis

UR - http://www.scopus.com/inward/record.url?scp=50849137854&partnerID=8YFLogxK

U2 - 10.1002/prca.200780163

DO - 10.1002/prca.200780163

M3 - Review

AN - SCOPUS:50849137854

SN - 1862-8346

VL - 2

SP - 974

EP - 988

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

IS - 7-8

ER -

Proteomic strategies in bladder cancer: From tissue to fluid and back

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this